Cottrell J J, Warner R D, McDonagh M B, Dunshea F R
Victoria University, Werribee, Australia.
J Anim Sci. 2004 Sep;82(9):2558-67. doi: 10.2527/2004.8292558x.
The hindlimb arteriovenous difference (AVD) model was used to determine whether 30 mg/ kg of the nitric oxide synthase (NOS) inhibitor L-NGnitroarginine methyl ester (hydrochloride; L-NAME) inhibited ovine NO synthesis and influenced muscle metabolism. Eight Border Leicester x Merino cross lambs (50 to 55 kg BW) were infused with saline (control) or saline containing L-NAME via an indwelling jugular vein catheter in a balanced randomized crossover design with 3 d between treatments. The abdominal aorta and deep femoral vein were catheterized for assessment of AVD of hind limb metabolism. Arterial hematocrit and insulin concentration and both arterial and venous concentrations of nitrate/nitrite (NOx), glucose, lactate, NEFA, and urea were determined. Infusion of L-NAME decreased arterial NOx concentrations (P = 0.049), indicating inhibition of systemic NO synthesis. Treatment had no effect on arterial (3.5 vs. 3.6 +/- 0.19 mmol/L for control and L-NAME lambs, respectively; P = 0.39) or venous (3.3 vs. 3.4 +/- 0.16 mmol/L, P = 0.55) plasma glucose concentrations or on glucose AVD (0.19 vs. 0.27 +/- 0.065 mmol/L, P = 0.20). There was an interaction (P = 0.038) between time and treatment, such that L-NAME initially increased the AVD of glucose (up to 180 m) divergent from control lambs. The response was then decreased before a possible inflection beyond 240 min. Infusion of L-NAME increased hindlimb venous NEFA (222 vs. 272 +/- 13.2 micromol/L, P = 0.007) and NEFA AVD (79.4 vs. -13.3 +/- 31.5 micromol/L, P = 0.018). These metabolic changes were independent of plasma insulin concentrations, which were not affected by L-NAME infusion (25.3 vs. 27.8 +/- 3.62 mU/L, P = 0.85). The increase in hindlimb lipolysis after L-NAME infusion does not seem to be due to increased lipolysis of plasma triacylglycerol because circulating arterial (155 vs. 142 +/- 20.8 micromol/L, P = 0.58), venous (154 vs. 140 +/- 20.5 micromol/L, P = 0.50), and AVD (1.0 vs. 2.9 +/- 3.17 micromol/L, P = 0.38) triacylglycerol concentrations were unaffected by L-NAME infusion. In conclusion, these data indicate that infusion of 30 mg of L-NAME/kg inhibits NO synthesis, which in turn influences fat and carbohydrate metabolism in the ovine hindlimb independently of plasma insulin concentrations.
采用后肢动静脉差异(AVD)模型来确定30毫克/千克的一氧化氮合酶(NOS)抑制剂L-硝基精氨酸甲酯(盐酸盐;L-NAME)是否会抑制绵羊体内一氧化氮的合成并影响肌肉代谢。八只边境莱斯特×美利奴杂交羔羊(体重50至55千克)通过留置颈静脉导管以平衡随机交叉设计输注生理盐水(对照组)或含L-NAME的生理盐水,两次治疗之间间隔3天。将腹主动脉和股深静脉插管以评估后肢代谢的AVD。测定动脉血细胞比容、胰岛素浓度以及动脉和静脉中硝酸盐/亚硝酸盐(NOx)、葡萄糖、乳酸、非酯化脂肪酸(NEFA)和尿素的浓度。输注L-NAME可降低动脉NOx浓度(P = 0.049),表明全身一氧化氮合成受到抑制。治疗对动脉(对照组和L-NAME处理组羔羊分别为3.5与3.6±0.19毫摩尔/升;P = 0.39)或静脉(3.3与3.4±0.16毫摩尔/升,P = 0.55)血浆葡萄糖浓度或葡萄糖AVD(0.19与0.27±0.065毫摩尔/升,P = 0.20)均无影响。时间与治疗之间存在交互作用(P = 0.038),使得L-NAME最初会使葡萄糖的AVD升高(在180分钟时),与对照组羔羊不同。随后该反应下降,在240分钟之后可能出现拐点之前。输注L-NAME可增加后肢静脉NEFA(222与272±13.2微摩尔/升,P = 0.007)以及NEFA AVD(79.4与 - 13.3±31.5微摩尔/升,P = 0.018)。这些代谢变化与血浆胰岛素浓度无关,L-NAME输注对其无影响(25.3与27.8±3.62毫国际单位/升,P = 0.85)。L-NAME输注后后肢脂肪分解增加似乎并非由于血浆三酰甘油的脂肪分解增加,因为循环动脉(155与142±20.8微摩尔/升,P = 0.58)、静脉(154与140±20.5微摩尔/升,P = 0.50)以及AVD(1.0与2.9±3.17微摩尔/升,P = 0.38)三酰甘油浓度均不受L-NAME输注的影响。总之,这些数据表明,输注30毫克/千克的L-NAME可抑制一氧化氮合成,进而独立于血浆胰岛素浓度影响绵羊后肢的脂肪和碳水化合物代谢。